Opdivo (nivolumab) plus low-dose Yervoy demonstrates continued survival benefit
Bristol-Myers Squibb announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma. February 11, 2019
